Health-Related Quality of Life (HRQL) in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) Treated with Cemiplimab: Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial

Main Article Content

Michael Migden
Danny Rischin
Medha Sasane
Vera Mastey
Anna Pavlick
Chrysalyne Schmults
Zhen Chen
Alexander Guminski
Axel Hauschild
Denise Bury
Anne Lynn Chang
Guilherme Rabinowits
Sheriff Ibrahim
Israel Lowy
Matthew Fury
Siyu Li
Chieh-I Chen


Skin Cancer, Squamous Cell Carcinoma, Biologic, PD-1 Inhibitor, Cemiplimab, Quality of Life


Abstract not available.


1. Karia PS et al. J Am Acad Dermatol. 2013;68:957–966.

2. Rogers HW et al. JAMA Dermatol. 2015;151:1081–1086.

3. Que SK et al. JAAD. 2018;78:237–247.

4. Ahmed SR et al. Expert Rev Clin Pharmacol. 2019;12:947–951.

5. Migden MR et al. N Engl J Med. 2018;379:341–351.

6. Rischin D et al. Ann Oncol. 2019;30(suppl 5):536–537.

7. Migden MR et al. J Clin Oncol. 2019;37(15 suppl):6015.

8. Migden MR et al. Lancet Oncol. 2020;21:294–305.

9. Aaronson NK et al. J Natl Cancer Inst. 1993;85:365–376.

10. Mills KC et al. Arch Dermatol. 2012;148:1422–1423.

11. Osoba D et al. J Clin Oncol. 1998;16:139–144.

12. Scott NW et al. EORTC QLQ-C30 Reference Values. 2nd ed. Brussels, Belgium: EORTC Quality of Life Group. 2008. Available at: